Association between COX-2 expression and effectiveness of COX-2 inhibitors in a phase ii trial in patients with metastatic colorectal adenocarcinoma

Anticancer Research

Volumn 32, Issue 8, 2012, Pages 3559-3564

  Almhanna, Khaldoun ^a   El Rayes, Bassel ^b   Sethi, Seema ^c   Dyson, Gregory ^c   Heilbrun, Lance ^c   Philip, Philip A ^c   Sarkar, Fazlul ^d  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b EMORY UNIVERSITY   (United States)

^c WAYNE STATE UNIVERSITY   (United States)

^d NONE

Author keywords

Celecoxib; COX 2; Metastatic colorectal cancer

Indexed keywords

CAPECITABINE; CELECOXIB; CYCLOOXYGENASE 2; IRINOTECAN;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CARDIOVASCULAR DISEASE; COLORECTAL CARCINOMA; DRUG EFFICACY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; METASTASIS; MULTIPLE CYCLE TREATMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SURVIVAL TIME; TREATMENT RESPONSE;

ADENOCARCINOMA; COHORT STUDIES; COLORECTAL NEOPLASMS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM METASTASIS;

EID: 84865675069     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ: Cancer statistics, 2009. CA Cancer J Clin 59: 225-249, 2009.
2. Grothey A and Sargent D: Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line. J Clin Oncol 23: 9441-9442, 2005.
3. Williams CS, Mann M and DuBois RN: The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 18: 7908-7916, 1999.
4. Fenwick SW, Toogood GJ, Lodge JP and Hull MA: The effect of the selective cyclooxygenase-2 inhibitor rofecoxib on human colorectal cancer liver metastases. Gastroenterology 125: 716-729, 2003.
5. Oshima M, Murai N, Kargman S, Arguello M, Luk P, Kwong E, Taketo MM and Evans JF: Chemoprevention of intestinal polyposis in the Apcdelta716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor. Cancer Res 61: 1733-1740, 2001.
6. Sheehan KM, Sheahan K, O'Donoghue DP, MacSweeney F, Conroy RM, Fitzgerald DJ and Murray FE: The relationship between cyclooxygenase-2 expression and colorectal cancer. JAMA 282: 1254-1257, 1999.
7. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M and DuBois RN: Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 93: 705-716. 1998.
8. Masunaga R, Kohno H, Dhar DK, Ohno S, Shibakita M, Kinugasa S, Yoshimura H, Tachibana M, Kubota H and Nagasue N: Cyclooxygenase-2 expression correlates with tumor neovascularization and prognosis in human colorectal carcinoma patients. Clin Cancer Res 6: 4064-4068, 2000.
9. Bamba H, Ota S, Kato A, Kawamoto C and Fujiwara K: Prostaglandins up-regulate vascular endothelial growth factor production through distinct pathways in differentiated U937 cells. Biochem Biophys Res Commun 273: 485-491, 2000.
10. Soumaoro LT, Uetake H, Higuchi T, Takagi Y, Enomoto M and Sugihara K: Cyclooxygenase-2 expression: a significant prognostic indicator for patients with colorectal cancer. Clin Cancer Res 10: 8465-8471, 2004.
11. Xiong B, Sun TJ, Hu WD, Cheng FL, Mao M and Zhou YF: Expression of cyclooxygenase-2 in colorectal cancer and its clinical significance. World J Gastroenterol 11: 1105-1108, 2005.
12. Haile RW, Yochim JM, Cortessis VK, Lin J, Levine A. J, Diep A, Danenberg K and Danenberg P: A molecular/epidemiologic analysis of expression of cyclooxygenases 1 and 2, use of nonsteroidal antiinflammatory drugs, and risk of colorectal adenoma. Clin Colorectal Cancer 4: 390-405, 2005.
13. Chan AT, Ogino S and Fuchs CS: Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med 356: 2131-2142, 2007.
14. El-Rayes BF, Zalupski MM, Manza SG et al: Phase-II study of dose attenuated schedule of irinotecan, capecitabine, and celecoxib in advanced colorectal cancer. Cancer Chemother Pharmacol 61: 283-289, 2008.
15. Sethi S, Macoska J, Chen W and Sarkar FH: Molecular signature of epithelial-mesenchymal transition (EMT) in human prostate cancer bone metastasis. Am J Transl Res 3: 90-99, 2010.
16. Khor LY, Bae K, Pollack A et al: COX-2 expression predicts prostate-cancer outcome: analysis of data from the RTOG 92-02 trial. Lancet Oncol 8: 912-920, 2007.
17. Edelman MJ, Watson D, Wang X et al: Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy - Cancer and Leukemia Group B Trial 30203. J Clin Oncol 26: 848-855, 2008.
18. Pantaleo MA, Astolfi A, Nannini M et al: Gene expression profiling of liver metastases from colorectal cancer as potential basis for treatment choice. Br J Cancer 99: 1729-1734, 2008.
19. Midgley RS, McConkey CC, Johnstone EC et al: Phase III randomized trial assessing rofecoxib in the adjuvant setting of colorectal cancer: final results of the VICTOR trial. J Clin Oncol 28: 4575-4580, 2010.